Bispecific antibody class landscape in oncology, 2026 mid-year reference

Reference layout of the bispecific antibody class in oncology as of mid-2026. Includes approved assets across haematology and solid tumours, the T-cell engager subclass, the dual-checkpoint subclass, and the live commercial questions including site-of-care infrastructure and combination strategy. Useful as a quick orientation for cross-functional teams entering the bispecific antibody conversation, with deeper analysis available in companion gated Briefs.